Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.

Alice Y.Y. Cheng, MD FRCPC Peter Lin, MD CCFP
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
DIABETES MEDICATION UPDATE A. Sami Wood, MS, RD/LD,CDE Center For Diabetes Education OSUMC.
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Combination Therapy in Type 2 Diabetes
Barriers to Diabetes Control Mark E. Molitch, MD.
Insulin therapy.
A1C 6.5 – 7.5% ** Monotherapy MET + GLP-1 or DPP4 1 TZD 2 Glinide or SU 5 TZD + GLP-1 or DPP4 1 MET + Colesevelam AGI Mos. *** Dual Therapy MET.
LONG TERM BENEFITS OF ORAL AGENTS
Afrezza® – inhaled human insulin
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
PHARMACOLOGICAL THERAPY FOR TYPE 2 DIABETES Reyhane Azizi M.D Assistant Prof. of Endocrinology and Metabolism Shahid Sadoghi University of Medical Sciences.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Guidelines for Diabetes Management September 20, 2012 Margaret Pochay RD CDE.
Titrating Insulin to Glycemic Target Judy Bowen, MD CIM Rotation September, 2006.
Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 3.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Diabetes Update Part 2 of 3 Division of Endocrinology
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2006 年 12 月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Diabetes Mellitus: Prevention & Treatment Medical surgical in nursing /02/01.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Insulin Optimisation Workshop Theingi Aung & Claire Rowell.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Special Situations In The Management Of In-Patient Hyperglycemia
INITIATION OF INSULIN THERAPY DR OKUNOWO EDM UNIT.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Small concise points on Insulin
Drugs for Type 2 Diabetes – where next after metformin ?
Diabetes Learning Event 7th October 2016
Copyright © 2015 by the American Osteopathic Association.
Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for.
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
James Thrasher, MD  The American Journal of Medicine 
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Recurrent falls in an older woman with diabetes
Luigi F. Meneghini, MD, MBA  The American Journal of Medicine 
Diabetes.
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use  David M. Kendall, MD, Robert M. Cuddihy, MD,
Sequential insulin strategies in type 2 diabetes.
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
James Thrasher, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Approach to starting and adjusting insulin in type 2 diabetes.
Insulin Delivery Systems Atlanta Diabetes Associates
Inpatient Insulin Management on the Wards
Insulin in Type 2 Diabetes
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology

Topics for Discussion Glycemic Targets Therapeutic Agents Case Discussion

Glycemic Targets American Diabetes Association American Association of Clinical Endocrinologists HbA1c Fasting glucose Post prandial glucose Hypoglycemia

Pharmacologic Agents Sulfonylureas and Meglitinides Metformin Alpha-glucosidase Inhibitors Thiazolidinediones Dipeptidyl Pepdidase-4 Inhibitors

Pharmacologic Agents Welchol Incretin Mimetic GLP-1 AgonistsGLP-1 Analogs Amylin Analogs

Pharmacologic Agents Human Insulin Regular NPH Analog Insulin Rapid Basal Mix

Special Considerations Heart Disease Renal Impairment Liver Disease Frailty Weight Gain

Case Discussion

Case 1 56 year old man referred by cardiologist Diabetes diagnosed during hospitalization for acute MI associated with pulmonary edema BMI 32 NYHA Class III functional status

Case 1 HbA1c 8.6% Serum creatinine 1.3 Discloses that he “ain’t takin’ no damn shots!”

Case 1 Discussion Drug naive patient with ischemic heart disease and systolic dysfunction Confrontational needle-phobe

Case 1 Metformin: Will it get to goal? Sulfonylurea: Hypoglycemia concerns? TZD’s: Fluid retention? DPP-4 Inhibitors?

Case 2a 42 year old woman referred by friend Strong family history. Symptoms of post prandial fatigue. Currently at her highest body weight. Exercise is infrequent

Case 2a BMI 36 HbA1c 7.8% Expresses a good understanding of recommended lifestyle changes.

Case 2a Metformin Sulfonylurea TZD DPP-4 Injections???

Case 2b After successful adoption of healthy lifestyle changes and metformin she maintains HbA1c less than 6.5% over the next three years She presents for follow up to discuss options to address weight gain and diabetes BMI 32

Case 2b 9 months ago HbA1c 7.3% Metformin was titrated to 1000 mg bid 6 months ago HbA1c 6.4% Back on track with exercise and associated 6 pound weight loss

Case 2b 3 months ago HbA1c 7.1% Recent job change, stressed out. Feels certain she can get back on track without additional medicaiton Now HbA1c 7.8% Weight is up 12 pounds from last visit Very frustrated with weight gain and constant hunger

Case 2b Metformin titration to 2500 mg? Addition of Sulfonylurea? Addition of TZD? Addition of DPP-4 Inhibitor? Addition of Basal Insulin Addition of a GLP-1 Agent

Case 3a 40 year old man currently on Metformin and SU maximal dose FBG PPG HbA1c 8.2% BMI 27

Case 3a Addition of third oral agent? Addition of GLP-1/Amylin Introduction of insulin? Human vs. Analog? What kind of dosing regimen?

Case 3b Addition of basal insulin helped maintain good glycemic control over the next 18 months Now HbA1c 7.8% FBG PPG

Case 3b Oral agents? Mealtime insulin Mealtime amylin Should anything be discontinued?

Case 4a 38 year old man presents for assessment after family member tests a blood sugar of 400 He has already adopted many good dietary changes and saw the educator at the health department Blood sugars range from HbA1c 9.8% BMI 31

Case 4a Metformin with continued lifestyle modification? Combination agent? Insulin? GLP-1/Amylin?

Case 4b After 5 years of maintaining HbA1c <7% on combination Metformin+TZD blood sugars are elevated HbA1c 8.2% 15 pound weight gain over past 3-6 months

Case 4b Third oral agent? Insulin? GLP-1/Amylin?

Case 5 60 year old woman with type 2 diabetes for 2 years treated with SU HbA1c has ranged from % over that time. Currently it is 7.5% Recent attempts to titrate SU have lead to frequent hypoglycemia, particularly with exercise She has been trying to exercise to stop her steady weight gain of 20 pounds over the past year

Case 5 Metformin? DPP-4? TZD? Insulin? GLP-1/Amylin?

Case 6 36 year old woman recently relocated to your area presents for first visit Diabetes diagnosed last year. Subacute onset of symptoms with passive 15 pound weight loss Started on Metformin and titrated to 1000 mg twice daily with good response

Case 6 Over past two months she has had recurrence of symptoms Blood sugars frequently in the 300+ range No change in routine Has experienced a 25 pound passive weight loss HbA1c now 10.5%

Case 6 Additional oral therapy? GLP-1/Amylin? What is her diagnosis?

Thank you